Compare Natera Inc. Common Stock (NTRA) vs PayPal Holdings, Inc. (PYPL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs PayPal Holdings, Inc. — how do they compare? Natera Inc. Common Stock trades at $394 (market cap $57.03B), while PayPal Holdings, Inc. trades at $56.15 (market cap $48.05B). The key difference: Natera Inc. Common Stock is the larger of the two by market cap, and PayPal Holdings, Inc. pays a 1% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and PayPal Holdings, Inc. for 106 Days on average.
| NTRA | PYPL | |
|---|---|---|
Market Cap | $57.03B | $48.05B |
Volume | 1,131,157 | 7,905,570 |
Sector | Health | Financials |
52-Week High | $425.64 | $73.01 |
52-Week Low | $179.42 | $39.08 |
Typical Hold Time | 0 Days | 106 Days |
Enterprise Value | $56.18B | $50.20B |
Dividend Yield | — | 1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
PayPal trades at $56.10, up 0.09% with a bullish technical signal. The stock shows strong fundamentals with revenue growth from $31.8B in 2024 to $33.2B in 2025 and net income of $5.23B. Valuation metrics appear attractive with P/E of 10.62 and EV/EBITDA of 6.89. Recent Q2 2026 earnings beat expectations at $1.38 EPS versus $1.28 expected. The company maintains robust cash flow with $1.53B net cash flow in 2025 and recently announced a Meta partnership for AI-powered checkout.
PayPal presents a compelling value opportunity with reasonable valuation and solid financials, though faces competitive pressures in digital payments. Analyst consensus is mixed with 35.7% buy ratings but a $56.41 price target suggesting limited upside. Key risks include checkout competition and slowing growth, balanced by new CEO's turnaround focus on Venmo, BNPL, and cost efficiency initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About PayPal Holdings, Inc.
PayPal Holdings, Inc. operates as a technology platform company that enables digital and mobile payments on behalf of consumers and merchants. The Company offers online payment solutions. PayPal Holdings serves customers worldwide.
Read more on PYPL →
